SCHEDULE: Millennium Management Discloses 5.3% Stake in Vanda Pharmaceuticals

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has disclosed a beneficial ownership of 5.3% in Vanda Pharmaceuticals Inc., totaling 3,120,339 shares of common stock.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively reported beneficial ownership of 3,120,339 shares of Vanda Pharmaceuticals Inc. common stock.
• This ownership represents 5.3% of Vanda Pharmaceuticals Inc.'s outstanding common stock.
• The filing was made on June 30, 2025, for an event that occurred on June 27, 2025.
• The reporting persons share both voting and dispositive power over all 3,120,339 shares.
• The filing is a Schedule 13G, indicating that the securities were not acquired or held for the purpose of changing or influencing the control of Vanda Pharmaceuticals Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or prospects. The disclosure of a significant institutional stake could be viewed neutrally or slightly positively by the market.

Positives

• The disclosure of a significant 5.3% stake by a prominent investment firm like Millennium Management LLC may signal institutional confidence or interest in Vanda Pharmaceuticals Inc.

Future Outlook

NA

Management Comments

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Vanda Pharmaceuticals Inc., and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing is a standard disclosure of a significant ownership stake by an institutional investor in a publicly traded company within the pharmaceutical sector. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major investment firm like Millennium Management could influence investor perception and potentially the stock's trading volume or price.

Key Dates

Keywords

Vanda Pharmaceuticals, Millennium Management, Israel A. Englander, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investment, Pharmaceuticals